Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Injectable Buprenorphine During Transition Out of Prison
NCT06880718Phase 4Recruiting
- Sponsor
- Lifespan Biotech
- Start
- Feb 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of buprenorphine extended-release injection in opioid use disorder (OUD) (2 arms), sponsored by Lifespan Biotech. Primary endpoints: Preliminary Effectiveness: Post-release retention in MOUD treatment, Acceptability of Intervention Measure and 3 more. Started Feb 2026; status: recruiting.
02
Drugs
buprenorphine extended-release injection
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT06880718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06880718.